Market Closed -
OTC Markets
10:54:04 12/06/2024 pm IST
5-day change
1st Jan Change
0.000001
USD
0.00%
-99.00%
0.00%
U.S. Stem Cell, Inc. Announces Resignation of Charles Hart as Member of the Board of Directors
August 04, 2016 at 01:34 am IST
On August 1, 2016, Charles Hart was removed as a member of the Board of Directors of U.S. Stem Cell, Inc.
U.S. Stem Cell, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
15/23/15
CI
U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt
14/23/14
CI
U.S. Stem Cell, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
10/22/10
CI
U.S. Stem Cell, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
24/22/24
CI
U.S. Stem Cell, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
01/22/01
CI
U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt
31/22/31
CI
U.S. Stem Cell, Inc. Announces Management Changes
09/22/09
CI
U.S. Stem Cell, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
10/21/10
CI
U.S. Stem Cell, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
13/21/13
CI
U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt
16/21/16
CI
U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt
16/21/16
CI
U.S. Stem Cell, Inc.'s Equity Buyback announced on January 16, 2015, has expired.
31/20/31
CI
U.S. Stem Cell, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019
07/19/07
CI
Tranche Update on U.S. Stem Cell, Inc.'s Equity Buyback Plan announced on January 16, 2015.
07/19/07
CI
U.S. Stem Cell, Inc. Announces Resignation of Kristin Comella as a Member of the Board of Directors and Her Position as Chief Scientific Officer
07/19/07
CI
U.S. Stem Cell, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019
08/19/08
CI
Tranche Update on U.S. Stem Cell, Inc.'s Equity Buyback Plan announced on January 16, 2015.
08/19/08
CI
U.S. Stem Cell, Inc. Announces Earnings Results for the First Ended March 31, 2019
08/19/08
CI
Tranche Update on U.S. Stem Cell, Inc.'s Equity Buyback Plan announced on January 16, 2015.
08/19/08
CI
U.S. Stem Cell, Inc. Reports Earnings Results for the Fourth Quarter and Year Ended December 31, 2018
14/19/14
CI
Tranche Update on U.S. Stem Cell, Inc.'s Equity Buyback Plan announced on January 16, 2015.
14/19/14
CI
U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt
13/19/13
CI
U.S. Stem Cell, Inc. Announces Revenue Results for the Quarter and Financial Results for the Nine Months Ended September 30, 2018
08/18/08
CI
Tranche Update on U.S. Stem Cell, Inc.'s Equity Buyback Plan announced on January 16, 2015.
08/18/08
CI
U.S. Stem Cell, Inc. Appoints Phil Posa as Senior Vice President of U.S. & International Sales
11/18/11
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
U.S. Stem Cell, Inc. is a biotechnology company. The Company is focused on the discovery, development and subject to regulatory approval and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. The Company's product candidates are MyoCell, MyoCell SDF-1 and Adipocell. MyoCell and MyoCell SDF-1 product candidates are clinical therapies designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. MyoCell SDF-1 is similar to MyoCell except that the myoblast cells to be injected for use in MyoCell SDF-1 will be modified prior to injection by an adenovirus vector or non-viral vector. Adipocell product candidate is a cell therapy kit with multiple possible treatment applications using autologous adipose cells. It is also investigating the use of adipose cells in a variety of clinical applications.
More about the company
1st Jan change
Capi.
0.00% 661 +15.85% 12TCr +18.91% 11TCr +7.51% 2.28TCr -18.63% 2.07TCr -13.76% 1.64TCr -15.68% 1.65TCr -43.53% 1.58TCr +1.75% 1.35TCr +28.07% 1.17TCr
Bio Therapeutic Drugs
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
U.S. STEM CELL, INC. 
